Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 22, 2015 12:45 PM ET


Company Overview of Endo Pharmaceuticals Inc.

Company Overview

Endo Pharmaceuticals Inc. researches, develops, and sells pharmaceutical products. The company offers products for therapeutic areas that include pain management in the areas of postherpetic neuralgia, osteoarthritis, migraine, and chronic pain; urology and oncology for non-muscle invasive bladder and prostate cancer; and endocrinology for central precocious puberty and hypogonadism. It also provides clinical trials. The company was formerly known as Endo Laboratories LLC and changed its name to Endo Pharmaceuticals Inc. in 1997. The company was founded in 1920 and is based in Malvern, Pennsylvania. Endo Pharmaceuticals Inc. operates as a subsidiary of Endo International plc.

1400 Atwater Drive

Malvern, PA 19355

United States

Founded in 1920





Key Executives for Endo Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 47
Compensation as of Fiscal Year 2014.

Endo Pharmaceuticals Inc. Key Developments

Endo Pharmaceuticals Inc. Announces Launch of NATESTO(TM)

Endo Pharmaceuticals Inc. announced the commercial availability of NATESTO(TM) (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. NATESTO(TM) was approved by the U.S. Food and Drug Administration (FDA) in May 2014 for replacement therapy in adult men with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). NATESTO(TM) reduces the risk of transference via intranasal application. The launch of NATESTO(TM) further expands Endo's branded portfolio of men's health treatment offerings and highlights continuing commitment to ensuring that patients living with hypogonadism have access to high quality medicines. In 2014, Endo acquired the rights to NATESTO(TM) in the U.S. and Mexico from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation, for $25 million plus additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding NATESTO(TM).

U.S. Food and Drug Administration accepts Endo Pharmaceuticals Inc.'s New Drug Application

Endo Pharmaceuticals Inc. and BioDelivery Sciences International Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the companies' BELBUCA(TM) (buprenorphine HCl) buccal film under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. FDA has indicated a standard review designation for the NDA and therefore the action date is expected 10 months from the NDA submission (October 2015). Additionally, the FDA recently accepted BELBUCA as the proprietary name for (buprenorphine HCl) buccal film.

Endo Pharmaceuticals Inc. and BioDelivery Sciences International, Inc. Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain

Endo Pharmaceuticals Inc. and BioDelivery Sciences International, Inc. announced that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The drug uses BDSI's patented BioErodible MucoAdhesive (BEMA®) drug delivery technology to efficiently and conveniently deliver buprenorphine across the buccal mucosa (inside lining of the cheek). Buprenorphine, a Schedule III controlled substance, is a partial opioid agonist and a potent analgesic with a relatively long duration of action. Buprenorphine HCl Buccal Film is being developed and will be commercialized through a worldwide license and development agreement between Endo Pharmaceuticals and BDSI. The two pivotal phase 3 studies for demonstration of safety and efficacy were double-blind randomized, placebo-controlled, enriched-enrollment studies in patients with chronic lower back pain. One study (BUP-307) was conducted in opioid experienced subjects, and the second study (BUP-308) was conducted in subjects naïve to opioid therapy. Both studies met the primary efficacy endpoint of change from baseline to week 12 of mean daily pain intensity score from placebo (BUP- 307; p <0.00001; BUP 308; p= 0.001). Buprenorphine HCl Buccal Film was generally well tolerated demonstrating a low incidence of typical opioid like side effects.

Similar Private Companies By Industry

Company Name Region
Mitsubishi Pharma America, Inc. United States
Pharmaceutical Associates, Inc. United States
Achelios Therapeutics LLC United States
Ndal Manufacturing Industries, Inc. United States
Alevium Pharmaceuticals Inc. United States

Recent Private Companies Transactions

May 1, 2015
Endo Pharmaceuticals Inc., Antipsychotic Risperidone
June 2, 2014
Endo Pharmaceuticals Inc., Early Stage Drug Discovery Portfolio

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Endo Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at